Section 232 specialty pharmaceuticals: zero-rate carveouts and Sept 29 HTSUS changes

BIS has published guidance that operationalizes the specialty-pharmaceutical zero-rate path under Proclamation 11020 (91 FR 18183; FR Doc. 2026-06956). The implementing notice is 91 FR 60360 (FR Doc. 2026-19498; published September 23, 2026).

Proclamation 11020 imposed a 100 percent ad valorem Section 232 tariff on certain patented pharmaceuticals and associated pharmaceutical ingredients, effective July 31, 2026 for companies listed in Annex III and September 29, 2026 for all other companies. At this time, Section 232 pharmaceutical tariffs do not apply to generic pharmaceutical products and associated ingredients.

Specialty pharma zero rate if product of an eligible jurisdiction or Commerce-approved urgent U.S. health need. HTSUS mods (including 9903.04.70) effective 12:01 a.m. ET September 29, 2026.

What counts as specialty under clause 3(d)

The Sep 23 notice defines the clause 3(d) specialty categories for zero-rate eligibility (definitions are for Proclamation 11020 purposes only):

• Orphan-only: drugs/biologicals where all approved or licensed indications are orphan-designated
• Nuclear medicines (radioactive drugs / related biologics as defined)
• Plasma-derived therapies
• Fertility drugs
• Cell therapy products and gene therapy products
• Antibody-drug conjugates (ADCs)
• CBRN medical countermeasures (chemical, biological, radiological, nuclear threats)
• Animal health pharmaceutical products

Zero rate applies when those products (and associated ingredients) are products of an eligible jurisdiction with a current or forthcoming trade and security framework agreement, or when they meet an urgent U.S. health need as determined under the notice's procedures.

Eligible jurisdictions (as listed Sep 23)

Urgent U.S. health need: how to request

Email BIS at pharma232@bis.doc.gov. One specific product per application. Include organization contacts; 10-digit HTSUS if possible; brand/IND and active ingredient(s); specialty category; country of origin and export; IOR name and number; manufacturer; and the urgent-need rationale (disease, alternatives, U.S. patient use, availability elsewhere). Requests cover patented products under Annex I HTSUS codes. Commerce consults USTR and HHS, decides company-specifically, notifies in writing, and transmits relevant information to CBP for entry-summary administration.

HTSUS technical corrections effective Sep 29

Annex I modifications are effective for goods entered, or withdrawn from warehouse, for consumption on or after 12:01 a.m. eastern time on September 29, 2026. Among the corrections: U.S. note 40 expands to include heading 9903.04.70 (zero ad valorem) for pharmaceutical articles under the enumerated classifications that are solely intended for clinical trials, research and development, or other non-commercial applications. Other corrections clarify generic articles (including unpatented animal health under 9903.04.67), the finished-product/API/KSM definition of pharmaceutical articles, heading 9903.04.69 residual coverage, Annex I HTS updates, and removal of overlapping Annex IV codes 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00, and 3004.49.00.

Importer and broker checklist

• Classification: confirm the line is in Annex I / U.S. note 40 coverage, and whether it is patented vs generic (generics currently outside the 232 pharma tariff).
• Specialty fit: map the product to a clause 3(d) definition before claiming the specialty zero path.
• Jurisdiction: document product-of-eligible-jurisdiction facts against the Sep 23 list (or later updates).
• Urgent need: if not jurisdiction-eligible, file the BIS package early; CBP may request entry-time documentation after Commerce approval.
• Entry summary coding: use the correct Chapter 99 heading (including new 9903.04.70 for clinical/R&D/non-commercial where applicable) effective 12:01 a.m. ET Sep 29, 2026.

This article does not opine on drawback eligibility for the Section 232 pharmaceutical layer. Run that analysis separately under 19 U.S.C. § 1313 and 19 CFR Part 190; do not assume steel/aluminum 232 drawback treatment automatically applies.

This article is for general information and is not legal or tax advice. Drawback eligibility depends on your specific facts, and final refunds are determined by CBP at liquidation. Consult a licensed customs broker or attorney for your situation.